Effective strategies for preventing trastuzumab mediated cardiac toxicity would allow more HER2+ breast cancer patients to successfully complete their adjuvant chemotherapy, while avoiding delays or discontinuation of vital therapy. This evidence concerns the gene ERBB2 and breast carcinoma.